Tirzepatide
FDA-approved dual GLP-1/GIP agonist — the gold-standard weight loss peptide with proven clinical results.
Category
Weight Loss (GLP-1/GIP)
Frequency
Once weekly injection
Research
FDA Approved (Mounjaro/Zepbound)What is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly and sold commercially as Mounjaro (for type 2 diabetes) and Zepbound (for obesity). It was FDA approved in 2022, making it the best-studied weight loss peptide with the most extensive clinical safety data.
The SURMOUNT-1 clinical trial demonstrated an average weight reduction of 22.5% (up to 26.6% in the highest dose group) over 72 weeks — results that had never been seen with any pharmaceutical or peptide before Retatrutide. It rapidly became the most prescribed weight loss medication in the United States.
In Vietnam, research-grade Tirzepatide is available at a fraction of the cost of branded Mounjaro. For users who want proven results with robust safety data and would prefer the next step up from Semaglutide, Tirzepatide is typically the first recommendation.
How It Works
GLP-1 Agonism: Activates GLP-1 receptors to suppress appetite, slow gastric emptying, improve insulin secretion, and reduce blood sugar. This is the same receptor targeted by Semaglutide (Ozempic).
GIP Agonism: GIP receptors in adipose tissue and the brain appear to work synergistically with GLP-1 to enhance the appetite-suppressing effects. GIP agonism also appears to reduce some of the GLP-1-induced nausea, giving Tirzepatide a better tolerability profile than pure GLP-1 agonists.
Together these two mechanisms produce metabolic effects significantly greater than either alone — a phenomenon called receptor co-agonism.
Benefits
- 22.5% average weight reduction in SURMOUNT-1 trial
- FDA approved with extensive Phase 3 clinical safety data
- Better GI tolerability vs Semaglutide (due to GIP co-agonism)
- Improved glycemic control for diabetic and pre-diabetic users
- Cardiovascular risk reduction (ongoing trials)
- Once-weekly dosing
- Strong appetite suppression with reduction in food cravings
Dosing Protocol
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Starting | 2.5mg | Once weekly | Weeks 1–4 |
| Titration 1 | 5mg | Once weekly | Weeks 5–8 |
| Titration 2 | 7.5mg | Once weekly | Weeks 9–12 |
| Titration 3 | 10mg | Once weekly | Weeks 13–16 |
| Maintenance | 10–15mg | Once weekly | Ongoing |
Always start at the lowest effective dose and titrate up gradually.
Side Effects
Common
- ⚠Nausea (most common, typically mild with proper titration)
- ⚠Diarrhea
- ⚠Vomiting (usually during dose increases)
- ⚠Constipation
- ⚠Decreased appetite
- ⚠Injection site reactions
Rare
- •Pancreatitis (rare but serious — seek immediate medical attention)
- •Gallbladder disease
- •Hypoglycemia (mainly in diabetics on insulin)
- •Acute kidney injury (from dehydration due to GI side effects)
Who Should NOT Use Tirzepatide
- ✕Personal or family history of medullary thyroid carcinoma (MTC)
- ✕Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- ✕History of severe pancreatitis
- ✕Type 1 diabetes
- ✕Pregnancy or breastfeeding
- ✕Severe gastrointestinal disease including gastroparesis
What to Expect
Mild nausea common. Appetite starts to reduce. Most users lose 1–3kg from water weight and reduced caloric intake.
Nausea typically resolved. Steady weight loss begins. Food cravings significantly reduced. Energy usually stable.
Consistent 0.5–1.5kg/week loss when combined with reasonable diet. Body composition clearly changing. Clothes fitting differently.
Weight loss slows as you approach a lower set point. Maintenance dose identified. Many users plateau around their new metabolic equilibrium.
FAQ
Q: Is generic Tirzepatide the same as Mounjaro?
A: The active molecule is identical. The difference is that branded Mounjaro goes through strict pharmaceutical manufacturing and regulatory oversight. Research-grade Tirzepatide varies in quality by supplier, which is why COA verification is essential.
Q: Should I choose Tirzepatide or Retatrutide?
A: Tirzepatide has superior clinical safety data and is FDA approved. Retatrutide shows higher weight loss (~6% more) but is still in Phase 3. For your first GLP-1 experience, Tirzepatide or Semaglutide is usually recommended.
Q: What if I plateau on Tirzepatide?
A: Plateaus are common after 3–6 months. Options include: increase dose to the next titration step, add resistance training, audit protein intake (aim for 1.6–2g/kg), or consider switching to Retatrutide for additional metabolic effect.
Q: Can I take Tirzepatide and BPC-157 together?
A: Yes, many users combine GLP-1 peptides with healing peptides like BPC-157. There are no known negative interactions. BPC-157 may even help with GI side effects from Tirzepatide.
Where to Get Tirzepatide in Vietnam
See our community-verified supplier list with COA verification and cold-chain shipping to Vietnam.
View Supply Index